<code id='EE6B13C14F'></code><style id='EE6B13C14F'></style>
    • <acronym id='EE6B13C14F'></acronym>
      <center id='EE6B13C14F'><center id='EE6B13C14F'><tfoot id='EE6B13C14F'></tfoot></center><abbr id='EE6B13C14F'><dir id='EE6B13C14F'><tfoot id='EE6B13C14F'></tfoot><noframes id='EE6B13C14F'>

    • <optgroup id='EE6B13C14F'><strike id='EE6B13C14F'><sup id='EE6B13C14F'></sup></strike><code id='EE6B13C14F'></code></optgroup>
        1. <b id='EE6B13C14F'><label id='EE6B13C14F'><select id='EE6B13C14F'><dt id='EE6B13C14F'><span id='EE6B13C14F'></span></dt></select></label></b><u id='EE6B13C14F'></u>
          <i id='EE6B13C14F'><strike id='EE6B13C14F'><tt id='EE6B13C14F'><pre id='EE6B13C14F'></pre></tt></strike></i>

          hotspot

          hotspot

          author:entertainment    Page View:39399
          Jeremey Wyatt ActiGraph

          As drugmakers wade into using digital health technologies, ActiGraph has made its mission to become the wearable of choice for the industry.

          The Pensacola, Fla.-based company creates  devices and software explicitly designed for clinical trials by focusing on features that matter to sponsors, like bulletproof reliability, access to raw sensor data, and 30-day battery life so that trial participants never have to worry about charging devices.

          advertisement

          There are many potential advantages to using wearables in clinical trials. Continuous data may collect a more comprehensive picture of how a patient responds to treatment and could help drugmakers complete trials faster with fewer participants. But risk-averse companies have been slow to adopt the technology and opt instead for the certainty of established methods for capturing data. The industry has yet to see a drug approved with evidence from a wearable device.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          comprehensive

          In age of alternative facts, a scholarly course on calling out crap
          In age of alternative facts, a scholarly course on calling out crap

          Screenshotviacallingbullshit.orgTiredofalternativefacts,fakenews,andbreathlesshyperbole,twoprofessor

          read more
          BMS, looking to build heart drug business, turns to AI for diagnosis
          BMS, looking to build heart drug business, turns to AI for diagnosis

          AdobeAsBristolMyersSquibbworkstobuilditstreatmentforaheartconditionthatcancausedifficultybreathingin

          read more
          Moonlake's readout produced a cash windfall. Risks remain
          Moonlake's readout produced a cash windfall. Risks remain

          MollyFerguson/STATFortwodaysstartingonSunday,MoonlakeImmunotherapeuticshappilycrunchednumbersandshar

          read more

          Sweeping indictment could be Trump's biggest legal challenge yet: ANALYSIS

          2:58FormerPresidentandRepublicanpresidentialcandidateDonaldTrumpreactsasheholdsacampaignrallyinErie,